Condition: DLBCL · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom
This description comes directly from the study's public registry record.
Weili Zhao · +86 021-64370045 · zwl_trial@163.com
Always discuss trial participation with your own doctor first.
| Beijing Hospital | Beijing, China | Not Yet Recruiting |
| The First Hospital Of Jilin University | Changchun, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, China | Not Yet Recruiting |
| Chenzhou No.1 People's Hospital | Chaozhou, China | Not Yet Recruiting |
| Sichuan Province People's Hospital | Chengdu, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, China | Not Yet Recruiting |
| Guangdong General Hospital | Guangzhou, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Recruiting |
| Hangzhou First People's Hospital | Hangzhou, China | Not Yet Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, China | Not Yet Recruiting |
| Shandong Cancer Hospital and Institute | Jinan, China | Not Yet Recruiting |
| Jiangxi Cancer Hospital | Nanchang, China | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06521255